## Highlights of This Issue  6953

### SPECIAL FEATURES

#### CCR Translations

**6955**  
**MAGE: The Spell Is Broken**  
Katayoun Rezvani  
*See article p. 7058*

#### CCR Drug Updates

**6958**  
**Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma**  
Evan J. Lipson and Charles G. Drake

#### Molecular Pathways

**6963**  
**Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells**  
Nicola Giuliani and Irma Airoldi

#### Perspective

**6971**  
**DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies**  
Graham A. Colditz and John Crowley

#### Reviews

**6973**  
**DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target**  
Shadid Jalal, Jennifer N. Earley, and John J. Turchi

**6985**  
**Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives**  
Jessica Godin-Ethier, Laila-Aicha Hanafi, Ciriaco A. Piccirillo, and Réjean Lapointe

### HUMAN CANCER BIOLOGY

**6992**  
**Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase 1**  
Trisha R. Sippel, Jason White, Kamalika Nag, Vadim Tsivian, Marcia Klaffen, B.K. Kleinschmidt-DeMasters, and Allen Waziri

**7003**  
**Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome**  

**7015**  
**Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma**  
David Z. Chang, Ying Ma, Baohan Ji, Huamin Wang, Defeng Deng, Yan Liu, James L. Abbruzzese, Yongjun Liu, Craig G. Logsdon, and Patrick Hwu

**7024**  
**Two Distinct Routes to Oral Cancer Differing in Genome Instability and Risk for Cervical Node Metastasis**  

**7035**  
**Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium**  
Hannah Barrow, Xiuli Guo, Hans H. Wandall, Johannes W. Pedersen, Bo Fu, Qicheng Zhao, Chen Chen, Jonathan M. Rhodes, and Lu-Gang Yu
CANCER THERAPY: PRECLINICAL

7047 Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
Yuhuan Li, Li-Xin Wang, Puiyi Pang, Zhihua Cui, Sandra Aung, Daniel Haley, Bernard A. Fox, Walter J. Urba, and Hong-Ming Hu

7058 Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
Conrad R. Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Andrea Sheehan, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Eslop, and Catherine M. Bollard
See commentary p. 6955

7067 Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells

7080 Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies

CANCER THERAPY: CLINICAL

7127 A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Xiangdong Liu, Qian Wang, Gengjie Yang, Cindy Marando, Holly K. Koblish, Leslie M. Hall, Jordan S. Fridman, Elham Behshad, Richard Wynn, Yu Li, Jason Boer, Sharon Diamond, Chunhong He, Meizhong Xu, Jincong Zhuo, Wenqing Yao, Robert C. Newton, and Peggy A. Scheele

IMAGING, DIAGNOSIS, PROGNOSIS

7139 Genetic Variation in Inflammatory Pathways Is Related to Colorectal Cancer Survival
Anna E. Coghill, Polly A. Newcomb, Elizabeth M. Poole, Carolyn M. Hutler, Karen W. Makar, Dave Duggan, John D. Potter, and Cornelia M. Ulrich

7148 A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendrogial Brain Tumors: A Report from EORTC Study 26951
Martin J. van den Bent, Lonneke A. Gravendeel, Thierry Gorlia, Johan M. Kros, Larisa Lapre, Pieter Wesseling, Johannes L. Teepen, Ahmed Idbaih, Marc Sanson, Peter A.E. Sillevis Smitt, and Pim J. French

CANCER THERAPY: CLINICAL

7156 Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhurgava, Toshiyuki Ise, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, and Jaap Verweij

7164 A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Malsa Mohbesh, Kwong-Yok Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole, Caroline Jochems, Jacquin Jones, Theresa Ferrara, Christopher B. Heery, Philip M. Arlen, Seth M. Steinberg, Mary Pazdur, Myrna Rauckhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlim, and James L. Gulley
GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy

Guru Sonpavde, Timothy C. Thompson, Rajul K. Jain, Gustavo E. Ayala, Shinji Kurosaka, Kohki Edamura, Ken-Ichi Tabata, Chengzheng Ren, Alexei A. Goltsov, Martha P. Mims, Teresa G. Hayes, Michael M. Ittmann, Thomas M. Wheeler, Adrian Gee, Brian J. Miles, and Dov Kadmon

Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437


Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer


ABOUT THE COVER

Human melanoma xenografts of UACC903 cells with activated BRAF mutation (V600E) were either untreated or treated with vehicle (DMSO) or the compounds riluzole, sorafenib, or riluzole with sorafenib. Upon termination of the experiment, the remaining tumors were excised and stained with activated caspase-3. This image is vehicle control. For details, see the article by Lee and colleagues on page 7080 of this issue.